NovaBridge Biosciences

NovaBridge Biosciences names Chuck Silberstein, M.D., M.B.A., as its new Chief Financial Officer, effective November 2, 2026. He replaces Kyler Lei, who is leaving after leading the company during his tenure. Silberstein brings combined medical and business expertise to the biotech firm.

Oct 2026NovaBridge BiosciencesNews article

NovaBridge Biosciences presents mature Phase 1b trial data for **givastomig**, a CLDN18.2 x 4-1BB bispecific antibody, combined with nivolumab and chemotherapy in **HER2-negative first-line metastatic gastroesophageal adenocarcinoma** patients. The findings, shared at **ESMO 2026**, advance the drug toward potential registrational development. The study evaluates efficacy and safety in late-stage gastric cancer, a high-unmet-need area.

Oct 2026NovaBridge BiosciencesNews article

Visara has obtained an exclusive option to acquire YOL104-2, a bioengineered peptibody designed to treat Ocular Surface Squamous Neoplasia (OSSN). The therapy combines interferon-mimetic properties with a trivalent, multifunctional structure, positioning it as a potential first-in-class treatment for the condition. Development focuses on addressing an unmet medical need in ophthalmology.

Oct 2026NovaBridge BiosciencesNews article

Visara secures exclusive worldwide rights (excluding Greater China) to develop and commercialize **HT006.2.2**, an investigational nerve growth factor therapy for **neurotrophic keratitis**, from Wuhan Hiteck Biological Pharma. The deal expands Visara’s ophthalmology pipeline with a novel treatment targeting corneal nerve damage. The therapy is currently in investigational stages, with no commercial availability confirmed.

Oct 2026NovaBridge BiosciencesNews article